Biomarin Pharmaceutical, Inc. (NASDAQ:BMRN) Q3 2022 Earnings Conference Call October 26, 2022 4:30 PM ET Company Participants Traci McCarty - VP, IR J.J. Bienaime - Chairman & CEO Jeffrey Ajer - EVP & Chief Commercial Officer Henry Fuchs - President, Worldwide Research & Development Brian Mueller - EVP, Finance & CFO Conference Call Participants Philip Nadeau - Cowen and Company Salveen Richter - Goldman Sachs Jessica Fye - JPMorgan Chase & Co. Srikripa Devarakonda - Truist Securities Paul Matteis - Stifel, ...

Table of Contents Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 BMRN The Nasdaq Global Select Market ______________________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ Form 10-Q ______________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANG ...

Call Start: 16:30 January 1, 0000 5:42 PM ET BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q2 2022 Earnings Conference Call August 3, 2022 16:30 ET Company Participants Traci McCarty - Vice President of Investor Relations J.J. Bienaime - Chairman and Chief Executive Officer Jeff Ajer - Executive Vice President and Chief Commercial Officer Hank Fuchs - President, Worldwide Research and Development Brian Mueller - Executive Vice President and Chief Financial Officer Greg Guyer - Executive Vice President and Chie ...

Table of Contents Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 BMRN The Nasdaq Global Select Market ______________________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ Form 10-Q ______________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANG ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2022 Earnings Conference Call April 27, 2022 4:30 PM ET Company Participants Traci McCarty - Vice President, Investor Relations J.J. Bienaime - Chairman and Chief Executive Officer Jeff Ajer - Executive Vice President and Chief Commercial Officer Hank Fuchs - President, Worldwide Research and Development Greg Guyer - Executive Vice President and Chief Technical Officer Brian Mueller - Executive Vice President and Chief Financial Officer Conference Call Participa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________ Form 10-K ____________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-26727 ____________ BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) D ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q4 2021 Results Conference Call February 23, 2022 4:30 PM ET Company Participants Traci McCarty - Vice President of Investor Relations J.J. Bienaime - Chairman and Chief Executive Officer Jeff Ajer - Executive Vice President and Chief Commercial Officer Hank Fuchs - President, Worldwide Research and Development Greg Guyer - Executive Vice President and Chief Technical Officer Brian Mueller - Executive Vice President, Chief Financial Officer Conference Call Particip ...

Table of Contents Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 BMRN The Nasdaq Global Select Market ______________________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ Form 10-Q ______________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANG ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q3 2021 Earnings Conference Call October 28, 2021 4:30 PM ET Company Participants J.J. Bienaime – Chairman and Chief Executive Officer Traci Mc Carty – Vice President of Investor Relations Jeff Ajer – Executive Vice President and Chief Commercial Officer Hank Fuchs – President worldwide research and development Reg Guyer – Executive Vice President Chief Financial Officer Brian Mueller – Executive Vice President, Chief Financial Officer Conference Call Participants ...

Table of Contents Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 BMRN The Nasdaq Global Select Market ______________________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ Form 10-Q ______________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANG ...